Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status &lt; 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital

Sen, R.; Islam, R. I.; Baker, H.; Kim, S.

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Use of single-agent pembrolizumab as first-line treatment for non-small cell lung cancer with PDL1 status < 50% as per NHS England interim guidance during the COVID-19 pandemic at Southend University Hospital

Sen, R.; Islam, R. I.; Baker, H.; Kim, S..

Lung Cancer ; 156:S18-S18, 2021.

Article in English | Web of Science | ID: covidwho-1274073

Search on Google

Print

XML

Collection: Databases of international organizations Database: Web of Science Language: English Journal: Lung Cancer Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Print

XML

Collection: Databases of international organizations Database: Web of Science Language: English Journal: Lung Cancer Year: 2021 Document Type: Article